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ABSTRACT
We proposed to examine the novel hypothesis that the hCG genotype of a woman's offspring is associated with her breast cancer risk. Using the existing Metropolitan New York Registry (MNYR) resources, a case-control study was designed to examine the hypothesis whether first-born offspring's hCGI3 5 genotype (i.e., placental hCG3 5 genotype during first full-term pregnancy) is associated with a woman's breast cancer risk. To date, the three tasks in the approved Statement of Work for year 1-3 have been accomplished. We have finished data analysis for the main results and we are in the process of manuscript preparation. 
INTRODUCTION:
It has long been known that both early age at first birth and total number of full-term pregnancies (FTPs) reduce breast cancer risk 1 5 . The underlying biology of this protection is yet to be clearly known. One or more of the hormonal changes during pregnancy are the logical candidates for this effect. Based on the published animal, human and epidemiological data, human chorionic gonadotropin (hCG), a glycoprotein hormone exclusively produced during pregnancy by the fetal part of placenta, has emerged as the most promising candidate6;7. The level of protection conferred by FTP may not be the same for all women, suggesting that there may be inherent variability in the protective effect across individuals. The hCG genes are well-known. Of the three trophoblastic hCG genes, hCGI3 5 is the most expressed gene in placenta, most highly conserved and the major contributor of hCG function during pregnancy 8;9. The genotype of the fetal placenta is actually the genotype of the developing fetus. We proposed to examine the novel hypothesis that the hCG genotype of a woman's offspring is associated with her breast cancer risk. The data and biospecimens for this study are banked in the repository of the Metropolitan New York Registry (MNYR), one of six collaborating sites of the NCI funded Cooperative Family Registry for Breast Cancer Studies (CFRBCS). Since 1995, MNYR assembled 1,150 families with more than 3,500 individuals. Using the existing MNYR resources, a case-control study was designed to examine the hypothesis whether firstborn offspring's hCGI3 5 genotype (i.e., placental hCGP 5 genotype during first FTP) is associated with a woman's breast cancer risk. We proposed to evaluate our hypothesis by comparing the hCGP3 5 genes of first-born children of women with breast cancer (cases) and women without breast cancer (controls).
BODY:
This is the final report for year 3 of the study. We have aimed to finish tasks 7-8 listed below during year 3 in the approved Statement of Work. To date, majority of the tasks for year 1-3 have been accomplished, and we are in the process of manuscript writing. For the proposed study, a separate database specific for this project has been created containing all relevant data. Cases and controls of breast Cancer and their older offspring with available blood samples were included in the proposed study. DNA samples of 297 cases and 237 controls and their older offspring were genotyped using fluorescent polarization technique to date for CSH1 rs2955245, CGB5 rs7260002, and CGB5 rs7246045 gene. Standard data cleaning and editing have been performed on these data to ensure that the case-control status.
To test the hypothesis that offspring's placental hormonal genotype is associated with risk of breast cancer in mothers, data were analyzed using unconditional logistic regression. We estimated adjusted odds ratios for breast cancer. Odds ratios were adjusted for race, age, ever HRT use, current HRT use, ever OC use, and number of live children of mother. Table 1 shows the relationship between CGB5 rs7260002 genotypes and maternal breast cancer status. We analyzed the data under three genetic models. Under both additive and dominant models, data suggested that offspring with C allele were more likely to have a mother with breast cancer. However, the elevated risk is not statistically significant. Table 2 shows the relationship between CSH1 rs2955245, CGB5 rs7246045 genotypes and maternal breast cancer status. For CGB5 rs7246045, we analyzed the data under dominant model, since the variant allele is rare. We did not observe an apparent association between offspring's CGB5 rs7246045 genotypes and maternal breast cancer. For CSH1 rs2955245, we analyzed the data under three genetic models. Under both additive and recessive models, data suggested that offspring with AA genotype were more likely to have a mother with breast cancer. However, the elevated risk is not statistically significant. Table 3 shows the effect of joint exposure to offspring's CGB5 rs7260002, CSH1 rs2955245 genes and maternal later age of giving first birth on risk of maternal breast cancer risk. Dichotomized categories for maternal later age of giving first birth was created based on median value in the data. For CGB5 rs7260002, we did not find that the effects of CGB5 rs7260002 C allele of offspring's and maternal later age of giving first birth were additive or beyond additive. On the other hand, for CSH1 rs2955245, elevated breast cancer risk was only elevated among those whose offspring with CSH1 rs2955245 A allele and who gave first birth later, suggesting the effects of the two exposures were additive. 
KEY RESEARCH ACCOMPLISHMENTS:
We examined the novel hypothesis that the hCG genotype of a woman's offspring is associated with her breast cancer risk and concluded the following:
Offspring's CSH1 rs2955245 A allele and CGB5 rs7260002 C allele may be positively associated with maternal breast cancer risk.
Relationship between offspring's CGB5 rs7246045 gene and maternal breast cancer risk is not clear.
We also found that women whose offspring with CSH1 rs2955245 A allele and who gave first birth later had a significant elevated risk of breast cancer, compared to those whose offspring with CSH1 rs2955245 G allele and who gave first birth earlier. This findings suggested the effects of later age of giving first birth and placenta CSH1 rs2955245 G allele may be additive. 
CONCLUSIONS:
This is the first study to evaluate hCG genotype of a woman's offspring and her breast cancer risk. In conclusion, preliminary analysis suggested offspring's CSH1 rs2955245 A allele and CGB5 rs7260002 C allele may be positively associated with maternal breast cancer risk. Relationship between offspring's CGB5 rs7246045 gene and maternal breast cancer risk is not clear. In addition, data also suggested interaction between these offspring's genes and maternal age at first birth on maternal breast cancer risk. Further analysis is in progress and results need confirmation in future studies. Larger sample size is needed for future studies. Additionally, future studies should consider effects of other maternal hormonerelated lifestyle factors in the analyses.
